
STRO Stock Forecast & Price Target
STRO Analyst Ratings
Bulls say
Sutro Biopharma has demonstrated significant progress in its pipeline, highlighted by the increased valuation of STRO-004 from $25 million to $50 million based on compelling preclinical data, positioning the company favorably ahead of its IND filing. The positive clinical data, particularly for Tivdak, which has shown substantial improvements in overall survival (OS), progression-free survival (PFS), and overall response rate (ORR), underscores the efficacy of its biotherapeutic offerings. With the pending full approval of Tivdak for metastatic cervical cancer in 2024, Sutro Biopharma's growth potential in the biopharmaceutical market appears robust.
Bears say
Sutro Biopharma faces significant challenges related to the efficacy of its therapeutic products, as the preferential binding of its antibodies to specific conformations may hinder their effectiveness in achieving uniform tumor targeting. This limitation is expected to adversely impact the performance of antibody-drug conjugates (ADCs), leading to potential issues with internalization, payload delivery, and overall treatment efficacy. Additionally, the negative ramifications seen with comparable therapies, such as off-tissue toxicity observed with Tivdak, raise concerns about the safety profile of Sutro's product pipeline.
This aggregate rating is based on analysts' research of Sutro Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.
STRO Analyst Forecast & Price Prediction
Start investing in STRO
Order type
Buy in
Order amount
Est. shares
0 shares